Should prostate-specific antigen velocity be abandoned?

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2011,（3）
• 页码范围: 359-360
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2011.34

摘要

Prostate-specific antigen (PSA) is the most widely used biomarker for prostate cancer, but may also be elevated in non-malignant conditions such as benign pro-static hyperplasia.Studies in the early 1990s suggested that rapid increases in PSA over time-a concept known as PSA velocity (PSAV)-may be useful to distinguish prostate cancer from the generally slower rise in PSA that may be seen in benign conditions.1 Subsequent studies demonstrated that PSAV predicts not only the presence of prostate cancer but also tumour grade, biochemical recurrence and disease-specific mortality.2,3 Accordingly, the National Comprehensive Cancer Network Guidelines suggest that PSAV should be considered along with PSA when considering whether to recommend a prostate biopsy.4